期刊文献+

彩色超声联合血浆miR-191、miR-21测定对上皮性卵巢癌的诊断效能 被引量:10

The diagnostic efficacy of color ultrasound combined with plasma miR-191 and miR-21 measurement for epithelial ovarian cancer
在线阅读 下载PDF
导出
摘要 目的分析彩色超声联合血浆miR-191、miR-21测定对上皮性卵巢癌的诊断效能。方法选取2019年1月—2020年2月四川省绵竹市人民医院妇科收治上皮性卵巢癌患者60例作为卵巢癌组,另外选取同期在医院治疗的上皮卵巢良性肿瘤患者60例为良性组,健康体检者60例为健康对照组。分析彩色超声、血浆miR-191、miR-21单独及其联合检测在上皮性卵巢癌诊断中的价值。结果彩色超声显示,卵巢癌组和良性组卵巢肿瘤直径比较差异无统计学意义(P>0.05),而质地、形状、位置及包膜完整度等比较差异有统计学意义(χ^2/P=34.816/<0.001,9.972/0.002,7.949/0.005,38.305/<0.001)。卵巢癌组血浆miR-191和miR-21表达水平高于良性组和健康对照组(F=212.468、689.846,P均<0.01);卵巢癌组血浆miR-191和miR-21表达水平随着肿瘤分期升高而增加(F=198.342、233.565,P均<0.01)。彩色超声诊断上皮性卵巢癌的AUC为0.748(95%CI 0.687~0.808),敏感度68.33%,特异度70.00%;血浆miR-191 AUC为0.595(95%CI 0.519~0.671),诊断的临界值为1.67,敏感度为61.67%,特异度为58.33%;血浆miR-21 AUC为0.703(95%CI 0.632~0.773),诊断的临界值为1.55,敏感度为65.00%,特异度为65.00%;三者联合检测的AUC为0.848(95%CI 0.801~0.895),敏感度为80.00%,特异度为58.33%。结论彩色超声联合血浆miR-191和miR-21检测上皮性卵巢癌,可有效提高敏感度,并保持较高的特异度和准确度,可弥补影像学的局限性。 Objective To analyze the diagnostic efficacy of color ultrasound combined with plasma miR-191 and miR-21 for epithelial ovarian cancer.Methods From January 2019 to February 2020,60 patients with epithelial ovarian cancer admitted to the Department of Gynecology,People's Hospital of Mianzhu City,Sichuan Province were selected as the ovarian cancer group,and 60 patients with benign epithelial ovarian tumors treated in the hospital during the same period were selected as the benign group and healthy physical examination 60 cases were healthy controls.To analyze the value of color ultrasound,plasma miR-191,miR-21 alone and in combination in the diagnosis of epithelial ovarian cancer.Results Color ultrasound showed that there was no statistically significant difference in the diameter of the ovarian tumor between the ovarian cancer group and the benign group(P>0.05),while the difference in texture,shape,location,and integrity of the envelope was statistically significant(χ^2/P=34.816/<0.001,9.972/0.002,7.949/0.005,38.305/<0.001).The expression levels of plasma miR-191 and miR-21 in the ovarian cancer group were higher than those in the benign group and the healthy control group(F=212.468,689.846,P<0.01);the expression levels of plasma miR-191 and miR-21 in the ovarian cancer group increased with the tumor stage Increased(F=198.342,233.565,P<0.01);color ultrasound diagnosis of epithelial ovarian cancer with AUC of 0.748(95%CI 0.687~0.808),sensitivity of 68.33%,specificity of 70.00%;plasma miR-191 AUC of 0.595(95%CI 0.519~0.671),the diagnostic cut-off value is 1.67,the sensitivity is 61.67%,the specificity is 58.33%;the plasma miR-21 AUC is 0.703(95%CI 0.632~0.773),and the diagnostic cut-off value is 1.55.The sensitivity is 65.00%and the specificity is 65.00%;the AUC of the three combined detection is 0.848(95%CI 0.801~0.895),the sensitivity is 80.00%,and the specificity is 58.33%.Conclusion Color ultrasound combined with plasma miR-191 and miR-21 to detect epithelial ovarian cancer can effectively improve the sensitivity,maintain high specificity and accuracy,and can make up for the limitations of imaging.
作者 张琳琳 黄仲萍 陈樑 陈玉 Zhang Linlin;Huang Zhongping;Chen Liang;Chen Yu(Department of Gynecology,Mianzhu People's Hospital,Sichuan Province,Mianyang 618200,China;不详)
出处 《疑难病杂志》 CAS 2020年第11期1133-1137,共5页 Chinese Journal of Difficult and Complicated Cases
基金 四川省科技计划项目(19ZDYF0701)。
关键词 上皮性卵巢癌 彩色超声 微小核糖核酸-191 微小核糖核酸-21 诊断效能 Epithelial ovarian cancer Color ultrasound miR-191 miR-21 Diagnostic value
  • 相关文献

参考文献10

二级参考文献55

  • 1EannistraSA. Cancer of the ovary[J]. N Engl J Med, 2004, 351 (24) : 2519-2529.
  • 2Ahmed FY, Wihshaw E, A' Hem RP, et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma[ J]. J Clin 9neol, 1996, 14(11): 2968-2975.
  • 3Ruvkun G. Molecular biology: Glimpses of a tiny RNA wor/d [ J ]. Science, 2001, 294(5543): 797-799.
  • 4Di Leva G, Croee CM. miRNA profiling of cancer [ J ]. Gun" Opin ~enet Dev, 2013, 23(1): 3-11.
  • 5Lawrie CH, Gal S, Dunlop HM, et al. "Detection ofelevated levels of tumour-associated microRNAs in serum ofpatients with diffuse large B-cell lymphoma" [ J]. Br J Haematol, 2008, 141 (5) : 672- 675.
  • 6Nam E J, Yoon H, Kim SW, et al. MicroRNA expression profiles in serous ovarian carcinoma[J]. Clin Cancer Res, 2008, 14(9) : 2690 -2695.
  • 7Kinose Y, Sawada K, Nakamura K, et al. The role of microRNAs in ovarian cancer[J]. Biomed Res Int, 2014, 2014: 249393.
  • 8Volinia S, Calin GA, Liu CG, et al. microRNA expression signa- ture of human solid tumors defines cancer gene targets [ J ]. Proc Natl Acad Sci U S A, 2006, 103(7) : 2257-2261.
  • 9Elyakim E, Sitbon E, Faerman A, et al. Hsa-miR-191 is a candi- date oncogene target for hepatocellular carcinoma therapy [ J 3. Cancer Res, 2010, 70(20): 8077-8087.
  • 10Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010 [ J]. CA Cancer J Clin,2010,60(5 ) :277-300.

共引文献433

同被引文献86

引证文献10

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部